Wall Street analyst estimates for Aprea Therapeutics, Inc. (APRE): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.08 | ||
| 2026-08-12 | $-0.07 | $-0.18 | +60.6% |
| 2026-05-13 | $-0.22 | $-0.23 | +4.3% |
| 2026-03-16 | $-0.32 | $-0.38 | +15.8% |
| 2025-11-12 | $-0.47 | $-0.11 | -327.3% |
| 2025-08-12 | $-0.53 | $-0.77 | +31.2% |
| 2025-05-14 | $-0.66 | $-0.65 | -0.9% |
| 2025-03-25 | $-0.49 | $-0.69 | +29.0% |
Valuation Ratios
| Price / Book | 0.41 |
| EV / EBITDA | 0.72 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | $583231 | $1.5M | 0 |
| Cost of Revenue | $7932 | $8316 | $170254 | $229610 | $271677 | $16.4M | $7052 | $9.4M | 0 |
| Gross Profit | -$7932 | -$8316 | -$170254 | -$229610 | -$271677 | -$16.4M | $576179 | -$7.9M | 0 |
| Research & Development | $13.4M | $14.2M | $21.0M | $37.9M | $23.9M | $92.4M | $7.6M | $9.4M | $7.0M |
| Selling, General & Admin | $2.5M | $2.3M | $8.4M | $14.9M | $13.6M | $21.0M | $8.4M | $6.5M | $6.5M |
| Operating Expenses | $15.9M | $16.5M | $29.4M | $52.8M | $37.2M | $97.0M | $16.0M | $6.5M | $13.2M |
| Operating Income | -$15.9M | -$16.5M | -$29.5M | -$52.8M | -$37.4M | -$113.4M | -$15.5M | -$14.3M | -$13.2M |
| EBITDA | -$15.2M | -$15.5M | -$27.9M | -$53.2M | -$36.9M | -$37.4M | -$14.3M | -$12.9M | -$12.6M |
| Interest Expense | $15 | $182 | $156351 | $222652 | 0 | $448667 | 0 | 0 | 0 |
| Pre-tax Income | -$15.2M | -$15.5M | -$28.1M | -$53.5M | -$37.1M | -$112.7M | -$14.3M | -$13.0M | -$12.6M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$15.2M | -$15.5M | -$28.1M | -$53.9M | -$36.5M | -$112.7M | -$14.3M | -$13.0M | -$12.6M |
| EPS | $-21.58 | $-22.06 | $-26.28 | $-50.61 | $-34.88 | $-1359.79 | $-3.95 | $-2.35 | $-1.93 |
| EPS (Diluted) | $-21.58 | $-22.06 | $-26.28 | $-50.61 | $-34.88 | $-1359.79 | $-3.95 | $-2.35 | $-1.93 |
| Shares Outstanding (Diluted) | $703783 | $703783 | $1.0M | $1.1M | $1.1M | $82852 | $3.6M | $5.5M | $6.5M |
Price
| Price | $0.73 |
| Market Cap | $9M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACXP · ADIL · APVO · BCDA · CELZ · GLTO · HCWB
Explore sector: Healthcare · Biotechnology
More sections of APRE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks